Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Immunotherapy Offers New Hope for Cancer Patients: One Man’s Alternative Cancer Treatment Journey
  • USA - English


News provided by

First Source Interactive

Dec 23, 2013, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Ray Merrill
Ray Merrill

I suffered through months where I couldn’t move, eat, or sleep, I was just a mess. If I had known about Perseus then, I wouldn’t have needed to go through that. That’s why I’m telling my story now, to try and help whoever I can.

Post this

Simpsonville, SC (PRWEB) December 23, 2013 -- It started as a mole on his leg, and spread quickly, despite aggressive chemotherapy and surgery. When 59-year-old Ray Merrill learned his melanoma was incurable and amputation of his leg was the only option available to buy just a little more time, he prayed for another solution. The alternative cancer treatment he found at Perseus PCI earlier this fall was literally the answer to his prayers, keeping his limb intact while bringing him immediate relief from pain, and in December, an extensive imaging test showed came back clear, showing no evidence of disease.

“My oncologist couldn’t believe it!” marvels Merrill. “Just a few months ago, I was headed straight to Stage 4 melanoma, with nothing but pain in the future. I was devastated, thinking I had no chance to see my 14-year-old daughter grow up.”

After receiving his ‘incurable’ diagnosis this fall, Merrill was determined not to spend whatever time he had left undergoing toxic chemotherapy regimens, or being bedridden after major surgery. Through his own extensive research and outreach, he learned of the Perseus PCI cancer vaccine.

“When I heard how it caused no side effects, I thought it was almost too easy to be real,” remembers Merrill. “Many people agreed with that conclusion and tried to talk me out of it, but I felt that this option was absolutely what I needed to do – it made sense and I was determined to try it. Hearing Dr. Wagner speak lifted my spirits and gave me hope, knowing there was a chance to beat this.”

Four months later, after completing the series of monthly inoculations, the soft-spoken Georgian native is certain his decision was the right, life-affirming one. From first to final treatment, all went smoothly, exactly as planned, and the most recent, completely clear PET (positron emission tomography) scan provided further evidence as to why Merrill feels better than he has in years.

With all the damage done by previous surgeries, including removal of lymph nodes, he had been in constant pain. The burning sensation on his legs made it difficult for him to function at his job as maintenance supervisor at a local eye center, or even sit for long periods of time. “Now I have my life back,” he reports. “The swelling on my leg is down, and the burning and pain is gone. I put in a full day at work, jog, ride my bike. My entire outlook has changed—I can now look forward to spending time with my daughter.”        

And while many hospitals and treatment centers work toward providing the ideal patient experience, Perseus actually delivers, according to Merrill. “I was treated like royalty,” says Merrill, “from the moment I stepped off the plane in the Cayman Islands. From the very beginning it was first class treatment, and everyone on staff was so knowledgeable and caring.”

After a simple blood draw, Merrill went back to the hotel to await his personalized immunotherapy vaccine. On the third day, he received his first injection of the serum, made from his blood and a small section of tumor taken from his biopsy sample. Then he flew home, feeling “absolutely fine, with not one side effect, not even the slight fever they warned me might happen.” Three subsequent visits at one-month intervals followed, and Merrill continued to recover as his skin healed and appetite and energy returned.

Already a veteran of chemotherapy used to treat the melanoma that had spread to his liver earlier this year, Merrill had endured its toxic effects firsthand. “I suffered through months where I couldn’t move, eat, or sleep, I was just a mess. If I had known about Perseus then, I wouldn’t have needed to go through that. That’s why I’m telling my story now, to try and help whoever I can.”

Says Dr. Thomas Wagner, the renowned biomedical scientist who created the Perseus cancer vaccine: “With patients like Ray, where the metastasis or spread of their tumor is still minimal, our vaccine can be very effective. It is my fervent hope that more patients will come to us at the earliest stage of their disease so we can see more and more dramatic recoveries like Ray’s.”

About the Perseus PCI Cancer Vaccine

The alternative cancer treatment was developed by Thomas Wagner, Ph.D., co-founder of Perseus PCI, a well-respected biomedical scientist and innovator responsible for pioneering some of the past half-century’s most important biomedical technologies. The Perseus PCI vaccine arms the immune system to destroy the tumor with the patient’s own T-cells, and creates a lifetime immunity to the disease. Approved by the Health Practice Commission of the Cayman Islands for research, the vaccine has gone through Phases I and II clinical trials in the U.S. for treatment of advanced stage melanoma, renal cell carcinoma and neuroblastoma. Additional trials of the immunotherapy treatment are being conducted in the U.S. and Europe through Orbis Health Solutions, LLC.

To learn more, visit http://www.perseuspci.com; or call 866-299-0750.

Danny Katz, First Source Interactive, http://www.firstsourceinteractive.com, (800) 672-1285 Ext: 3, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.